# Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

> **NCT04647461** · PHASE4 · UNKNOWN · sponsor: **CHA University** · enrollment: 61 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertensive

## Interventions

- **DRUG:** Brimonidine Tartrate 1.5mg
- **DRUG:** Brimonidine Tartrate 1.5mg

## Key facts

- **NCT ID:** NCT04647461
- **Lead sponsor:** CHA University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-20
- **Primary completion:** 2021-01-29
- **Final completion:** 2021-01-29
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04647461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04647461, "Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04647461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*